

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: October 30, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400051.

Dear Sir/Madam,

Subject: Revised Submission – Certificate for Non-Applicability of Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is with reference to our earlier submission made on October 08, 2025, regarding the Non-Applicability of Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We wish to inform you that the Company is submitting a revised disclosure along with a certificate issued by the Practicing Company Secretary, confirming that the provisions of Regulation 27(2) of the SEBI (LODR) Regulations, 2015 are not applicable to the Company for the financial year 2025–26.

In compliance with SEBI Master circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, attaching herewith PCS certificate w.r.t. non-applicability of the corporate governance provisions.

Kindly take this letter on your record and oblige us.

Thanking you,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Ms. Niyati Dipesh Parikh
Company Secretary & Compliance Officer
Place: Ahmedabad

Encl: A/a-

SCS and Co. LLP

Company Secretaries

To,
The Board of Directors,
Sotac Pharmaceuticals Limited
Plot No. PF-21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Ahmedabad, 382110, Gujarat

Subject: Certificate for Non-Applicability of Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year 2025-26

In accordance with Regulation 15 of the SEBI (LODR) Regulations, 2015, the provisions of Chapter IV shall apply to a listed entity which has listed its specified securities on any recognized stock exchange(s), either on the Main Board, SME Exchange, or Innovators Growth Platform. However, the compliance requirements for corporate governance as specified under Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 27, and clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46, along with Para C, D and E of Schedule V, are exempt for:

A. Companies having paid-up equity share capital not exceeding ₹ 10 crore and net worth not exceeding ₹ 25 crore as on the last day of the previous financial year; and


B. A listed entity which has listed its specified securities on the SME Exchange.


Since, Sotac Pharmaceuticals Limited is listed on the Emerge Platform of NSE India Limited, the provisions relating to Corporate Governance, including submission of the compliance report under Regulation 27(2) of the SEBI (LODR) Regulations, 2015, are not applicable to the Company for the financial year 2025-26, in line with Regulation 15(2)(b) read with Regulation 27(2) and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Accordingly, being a company listed on the SME Exchange, the compliance requirements under Regulation 27 of the SEBI (LODR) Regulations, 2015 are not applicable to Sotac Pharmaceuticals Limited.

This certificate is issued at the request of the Company for submission to the National Stock Exchange of India Limited.

For, SCS and Co. LLP
Company Secretaries
Firm Registration Number: - L2020GJ008700
Peer Review Number: - 5333/2023


Anjali Sangtani
Partner
M. No.: - A41942, COP: - 23630
UDIN: A041942G001695099
Date: - October 30, 2025
Place: - Ahmedabad



SCS and Co. LLP, a Limited Liability Partnership with LLP Identity No. AAV-1091
Firm Registration Number: - L2020GJ008700, Peer Review No. 5333/2023
Regd. Office: - Office No. B- 1310, Thirteenth floor, "Shilp Corporate Park" Rajpath Rangoli Road,
Thaltej, Ahmedabad, 380054
T: 079-40051702, Email: - scsandcollp@gmail.com Website: www.scsandcollp.com